EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Blood‐ and Liver Stiffness‐Based Non‐Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC

Lorenz Balcar iD, Tina Jasmin Haunold, Mathias Jachs iD, Georg Semmler iD, Benedikt Simbrunner iD, Albert Friedrich Stättermayer iD, David Pereyra iD, Christoph Schwarz, Stefan Stremitzer iD, Klaus Kaczirek iD, Patrick Starlinger, Peter Quehenberger iD und 5 weitere

Liver International · 2026-11 · 46 (11)

DOI: 10.1111/liv.70947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 26.10.2026. Verfasst von Lorenz Balcar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Hypertension, Portal, Liver Neoplasms, Carcinoma, Hepatocellular, Elasticity Imaging Techniques. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ludwig Boltzmann Gesellschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The applicability of non‐invasive tests (NITs) for clinically significant portal hypertension (CSPH) in patients with hepatocellular carcinoma (HCC) is controversial. We performed a head‐to‐head comparison of various NITs for CSPH and evaluated rule‐in/‐out criteria.

Methods

We conducted a retrospective study including 283 patients with HCC undergoing hepatic venous pressure gradient (HVPG) measurement at the Vienna Hepatic Haemodynamic Lab with available, same‐day data on NITs (i.e., liver stiffness measurement [LSM], platelet count [PLT], von Willebrand factor antigen [VWF:Ag], and the ratio of VWF:Ag and PLT [VITRO]). For the subsequent analysis, we focused on patients with compensated advanced chronic liver disease (cACLD).

Results

Among 164 patients with cACLD, most were BCLC 0/A (50.6%) and CSPH prevalence was 46.3%, the median LSM was 20.0 kPa (IQR: 13.3–37.9), and mean VWF:Ag/VITRO was 266 ± 119%/2.30 ± 1.81. The VITRO score yielded the highest discriminative ability to detect CSPH (AUROC: 0.834), followed by ANTICIPATE ± NASH (AUROC: 0.822), PLT (AUROC: 0.803), LSM (AUROC: 0.779), and VWF:Ag (AUROC: 0.707). The application of the Baveno VII criterium (LSM ≤ 15 kPa & PLT ≥ 150G/L) and the VITRO score (≤ 1.0) individually showed an excellent performance for ruling‐out CSPH (sensitivities: ≥ 95%, NPV: 100%/87.9%). For ruling‐in CSPH by individual criteria, the VITRO score provided the highest PPV (≥ 2.5, specificity/PPV: 89.8%/83.0%), followed by the Baveno VII criteria (specificity/PPV: 81.8%/74.6%). When sequentially applying Baveno VII criteria and VITRO, the grey zone could be significantly reduced to 16% (sensitivity/NPV: 94.7%/92.2%; specificity/PPV: 73.9%/84.4%).

Conclusion

The discriminative ability in patients with cACLD and HCC was comparable to patients without HCC. However, PPVs of established criteria were < 90%, which may be explained by the comparatively low prevalence of CSPH in this context.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PortalLiver NeoplasmsCarcinoma, HepatocellularElasticity Imaging TechniquesLiverHumansFemaleRetrospective StudiesMaleMiddle AgedAgedvon Willebrand FactorPlatelet CountLiver CirrhosisROC Curve

Stichwörter der Autor:innen

ACLDHCCVITROcirrhosisliver stiffnessvon Willebrand factor

Substanzen

von Willebrand Factor

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria.
  • Department of General Surgery, Medical University of Vienna, Vienna, Austria.
  • Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Lorenz Balcar, Mathias Jachs, Georg Semmler, Benedikt Simbrunner, Albert Friedrich Stättermayer, David Pereyra, Stefan Stremitzer, Klaus Kaczirek, Peter Quehenberger, Bernhard Scheiner, Thomas Reiberger, Matthias Pinter, Mattias Mandorfer

Förderung

  • Ludwig Boltzmann Gesellschaft

Zitieren

APA

Balcar, L., Haunold, T. J., Jachs, M., Semmler, G., Simbrunner, B., Stättermayer, A. F., Pereyra, D., Schwarz, C., Stremitzer, S., Kaczirek, K., Starlinger, P., Quehenberger, P., Trauner, M., Scheiner, B., Reiberger, T., Pinter, M., & Mandorfer, M. (2026). Blood‐ and Liver Stiffness‐Based Non‐Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC. Liver International, 46(11). https://doi.org/10.1111/liv.70947

Vancouver

Balcar L, Haunold TJ, Jachs M, Semmler G, Simbrunner B, Stättermayer AF, et al. Blood‐ and Liver Stiffness‐Based Non‐Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC. Liver International. 2026;46(11). doi:10.1111/liv.70947

BibTeX
@article{Balcar2026,
  author = {Balcar, Lorenz and Haunold, Tina Jasmin and Jachs, Mathias and Semmler, Georg and Simbrunner, Benedikt and Stättermayer, Albert Friedrich and Pereyra, David and Schwarz, Christoph and Stremitzer, Stefan and Kaczirek, Klaus and Starlinger, Patrick and Quehenberger, Peter and Trauner, Michael and Scheiner, Bernhard and Reiberger, Thomas and Pinter, Matthias and Mandorfer, Mattias},
  title = {Blood‐ and Liver Stiffness‐Based Non‐Invasive Tests for Clinically Significant Portal Hypertension in Patients With cACLD and HCC},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {11},
  doi = {10.1111/liv.70947}
}
Kostenlos starten →